CTDs, or connective tissue diseases, are a group of over 200 disorders that affect the tissues holding your body’s structures together. Connective tissue is everywhere: in your skin, joints, blood vessels, bones, and organs. When something goes wrong with it, whether from a faulty immune system, a genetic mutation, or abnormal cell growth, the effects can show up across multiple body systems. CTDs range from relatively mild joint looseness to serious, life-threatening organ damage.
The Three Main Categories of CTDs
Connective tissue diseases fall into three broad groups based on what causes them.
Autoimmune CTDs happen when your immune system mistakenly attacks your own connective tissue, triggering chronic inflammation. This group includes lupus, scleroderma, Sjögren’s syndrome, and rheumatoid arthritis. These are what most people picture when they hear “connective tissue disease.”
Genetic CTDs result from a gene mutation you’re born with that disrupts how connective tissue develops. The mutation typically affects collagen or elastin, the two primary building blocks of all connective tissue. Ehlers-Danlos syndrome, Marfan syndrome, and osteogenesis imperfecta (brittle bone disease) are the most well-known examples.
Connective tissue cancers are less commonly discussed but still fall under this umbrella. Certain soft tissue sarcomas grow in connective tissue like fat, muscle, or blood vessels.
Common Autoimmune CTDs
Autoimmune connective tissue diseases are rare individually but collectively affect roughly 5 to 97 people per 100,000, depending on the specific condition. Lupus (systemic lupus erythematosus) is the most common, with about 3.3 new cases per 100,000 people diagnosed each year in England. Scleroderma is rarer, at roughly 1.9 new cases per 100,000 annually.
Lupus can affect the joints, skin, heart, lungs, blood vessels, kidneys, and brain. It tends to flare and remit, meaning symptoms come and go in waves. Scleroderma causes the skin and internal organs to harden and tighten as excess collagen builds up. Sjögren’s syndrome primarily attacks the glands that produce tears and saliva, leading to severe dryness in the eyes and mouth, though it can also affect other parts of the body.
Genetic CTDs: Ehlers-Danlos and Beyond
Ehlers-Danlos syndrome (EDS) is actually a group of disorders caused by mutations in at least 20 different genes. The most recognizable feature is an unusually large range of joint movement, called hypermobility, which sounds harmless but leads to joints that are unstable, prone to dislocation, and chronically painful. Many people with EDS also have soft, stretchy skin that bruises easily and heals with unusual scarring.
The different types of EDS vary widely in severity. The hypermobile type mainly affects the joints and is the most common. The vascular type is the most dangerous, causing unpredictable ruptures of blood vessels and organs. The classical type produces wounds that split open easily and leave widened “cigarette paper” scars. Other types affect the spine, corneas, heart valves, teeth, or muscles. In infants and children, EDS often shows up first as weak muscle tone that delays sitting, standing, and walking.
Marfan syndrome, another genetic CTD, affects the body’s elastic fibers and typically causes a tall, thin build with long limbs and fingers, along with heart and eye problems.
Symptoms That Span Multiple CTDs
Because connective tissue exists throughout the body, CTDs tend to cause symptoms in more than one area at once. Several hallmark signs show up across different autoimmune CTDs.
Raynaud’s phenomenon is one of the most common early signs. Your fingers or toes turn white and go numb in response to cold or stress, then shift to blue or gray before flushing red as blood flow returns. In severe cases, the tissue at the fingertips can actually die. Swollen, puffy fingers and hands are another early signal, along with joint pain and swelling that can eventually cause joints to change shape. Red or brown patches over the knuckles sometimes appear as well.
Fatigue, muscle weakness, and general malaise are nearly universal across autoimmune CTDs. Many people also develop skin changes, from the butterfly-shaped facial rash of lupus to the tight, hardened skin of scleroderma.
Mixed and Undifferentiated CTDs
Not every case fits neatly into one diagnosis. Mixed connective tissue disease (MCTD) combines features of lupus, scleroderma, and an inflammatory muscle disease called polymyositis. What distinguishes MCTD as its own condition is the presence of a specific antibody targeting a protein called U1-RNP. People with MCTD tend to have higher rates of Raynaud’s phenomenon and a type of high blood pressure in the lungs (pulmonary hypertension), but less severe kidney involvement and a generally better overall prognosis than lupus alone.
Undifferentiated connective tissue disease (UCTD) is the term used when someone has clear signs of an autoimmune CTD but doesn’t yet meet the full criteria for any specific one. Over time, UCTD can evolve. Some people develop enough symptoms and lab markers to be reclassified with a defined disease. Others remain undifferentiated for years or even permanently.
How CTDs Are Diagnosed
Diagnosing autoimmune CTDs usually starts with a blood test called an ANA (antinuclear antibody) test, which checks whether your immune system is producing antibodies that attack your own cells. A positive ANA result doesn’t confirm any specific disease on its own, and it can even show up temporarily after a viral infection. A negative result makes an autoimmune disorder less likely but doesn’t completely rule one out.
If the ANA test is positive, more specific antibody tests help narrow things down. For scleroderma, doctors also use a scoring system that evaluates skin thickening on the fingers, fingertip ulcers or scars, visible clusters of tiny blood vessels (telangiectasia), abnormal blood vessels visible at the base of the fingernail, lung involvement, and Raynaud’s phenomenon. Skin thickening on both hands that extends past the knuckles is, on its own, enough to classify someone as having scleroderma under the current scoring system.
For most CTDs, diagnosis combines blood work, physical examination, imaging, and a detailed history of how symptoms have developed over time. Getting a clear diagnosis can take months or years, particularly when symptoms overlap between conditions.
Long-Term Effects on the Body
Left unmanaged, autoimmune CTDs can cause lasting damage to major organs. The lungs are particularly vulnerable: both scleroderma and MCTD can lead to scarring of lung tissue (interstitial lung disease) or elevated pressure in the blood vessels of the lungs. Kidney damage is a serious concern in lupus. Heart complications, including inflammation of the heart lining and valve problems, occur across several CTDs.
Some of the long-term damage comes not from the disease itself but from the medications used to control it. Years of treatment can contribute to bone thinning, cataracts, diabetes, and early menopause. This is why management typically aims to use the lowest effective level of treatment to keep inflammation in check while limiting side effects.
How CTDs Are Managed
There is no cure for most connective tissue diseases, but treatment can control symptoms and slow progression. For autoimmune CTDs, the core approach is reducing the immune system’s overactivity. This typically involves anti-inflammatory medications, drugs that broadly suppress the immune response, and in some cases, newer targeted therapies that block specific parts of the immune pathway driving inflammation.
Genetic CTDs like Ehlers-Danlos syndrome are managed differently, since the underlying issue is structural rather than immune-related. Treatment focuses on protecting vulnerable joints through physical therapy, avoiding activities that overextend them, and monitoring for complications specific to each type, such as blood vessel rupture in the vascular form.
For all CTDs, regular monitoring matters. Because these diseases can affect multiple organ systems and change over time, periodic blood work, lung function tests, and imaging help catch new problems early. Many people with CTDs live full lives with proper management, particularly when the disease is identified before significant organ damage has occurred.